Department of Translational Clinical Oncology
|Purpose of Research||Construct the clinical systems necessary for the safe, effective implementation of translational clinical oncology, and contribute to the progress of clinical oncology.|
|Details of Research||In collaboration with the Translational Research Center, research on clinical systems for the safe, effective implementation of translational clinical oncology required for the development of novel cancer treatment. Further, verification of whether or not improved treatment results and/or patient prognosis are observed through the implementation of clinical trials of the many novel cancer treatments developed in different research fields.|
|Sponsor||Taiho Pharmaceutical Co., Ltd.|
|Duration of Endowment||From October 2003 to September 2013|
Department of Immunology and Genomic Medicine
|Purpose of Research||Fundamental research on the structure of genetic variation in the immune system and its regulation, as well as research on novel treatments for a range of diseases using immunoregulatory factors.|
|Details of Research||In collaboration with Immunology and Cell Biology, the Center for Genomic Medicine, Hematology, Transplantation and Immunology, Rheumatology and Clinical Immunology, and oncology treatment projects in a number of clinical departments, carry out fundamental research on immunology and genomic medicine at the same time as offering a graduate-level education on the core content of immunology and genomic medicine with the aim of clinical applications for immunoregulatory substances.|
|Sponsor||Ono Pharmaceutical Co., Ltd.|
|Duration of Endowment||From April 2005 to March 2010|
Department of Organ Preservation Technology
|Purpose of Research||We research the mechanisms of functional deterioration of organs, tissues, and cells during preservation. Further, we develop novel methods and techniques to effectively preserve organs, tissues, and cells.|
|Details of Research||In collaboration with many departments mainly related to organ transplantation, such as Department of Thoracic Surgery and Department of Transplantation and Immunology, we carry out various research for elucidating the mechanisms of functional deterioration after preservation and improving the quality of organs, tissues, and cells to directly benefit patients for those advanced therapies. Further, knowledge on organ, tissue and cell preservation would also provide better results in regenerative medicine. We would like to collaborate in many research topics, and perform basic as well as pre-clinical studies.|
|Sponsor||Otsuka Pharmaceutical Co., Ltd.|
|Duration of Endowment||From August 2006 to July 2011|
Multidisciplinary Cancer Treatment(under construction)
Department of Epilepsy, Movement Disorders and Physiology
|Purpose of Research||
1) To solve pathophysiology of epilepsy and movement disorders, and to develop new treatments that could lead to the advanced medical care. It also aims at standardizing it in clinical practice in the near future.
2) To promote research of clinical neurophysiology on epilepsy and movement disorders and its clinical application, because basic- and clinical epileptology and movement disorders are very closely related to neurophysiological knowledge and methods.
3) To provide the integrated teaching opportunity for training of research-scientists, clinical specialists and leaders of related fields internationally.
|Details of Research||
In very close collaboration with Department of Neurology, Neurosurgery, Neuropsychiatry, Pediatrics, Human Brain Research Center, Radiology and iPS center in Kyoto University Graduate School of Medicine and Hospital, we shall 1) clarify pathophysiology of epileptogenicity and movement disorders, 2) introduce new treatment approach, 3) enhance clinical diagnostic quality, 4) promote basic research directly related to clinical question, 5) promote individualized drug treatment based on gene analysis, and finally integrated system are aimed to solve clinical questions.
|Sponsor||GlaxoSmithKline K.K., Nihon Kohden Co., Otsuka Pharmaceutical Co., UCB Japan Co. Ltd.,|
|Duration of Endowment||
From August 2013 to May 2018
Department of Clinical System Onco-Informatics
|Purpose of Research||In collaboration with the Kyoto University Hospital Cancer Center Biobank & Informatics for Cancer Project, which has established a protocol for longitudinal recording of clinical data as well as collection and storage of blood samples, the laboratory aims to develop new methods for integration and analysis of various types of biological data, and in doing such, provide frameworks that enable clinical data to spur the creation of translational clinical informatics and data-driven personalized medicine.
The functional consequences are new methods for systematic, rational inference about each individual cancer patient’s physical state, efficacy of treatment, and prediction of drug adverse events, leading to improved therapies at an individual level.
Further, related research for novel biomarker and drug target discovery will be conducive to development for both higher-level medicine and pharmaceutical research.
|Details of Research||1) Development of prediction models for per-patient physical state, efficacy of treatment, and prediction of drug adverse events.
2) Development of computational algorithms for derivation of optimal therapy processes for individual patients.
3) Development of high-speed data mining methods of big data acquired from actual clinical practice.
|Research Topics||1) Statistical and mathematical models for integrated analysis of time-series clinical data and biological information.
2) High-speed algorithms to enable data mining of big data acquired from actual clinical practice.
3) Prediction models for per-patient physical state, efficacy of treatment, and prediction of drug adverse events.
4) Discovery of novel biomarkers and druggable targets based on integrated analysis of clinical time-series data and biological information.
5) Computationally-guided therapy process optimization for individual patients, to drive logical inference of therapy strategies and clinical trial strategies.
|Sponsors||Chugai Pharmaceutical Co., Ltd. and Mitsui Knowledge Co., Ltd.|
|Duration of Endowment||April 2014 through March 2017|